{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patanol&page=2",
    "query": {
      "intervention": "Patanol",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patanol&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T09:07:39.781Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01495338",
      "title": "A Comparison of the Safety and Comfort of AC-170",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Ocular Health"
      ],
      "interventions": [
        {
          "name": "AC-170 0.17%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24% (Formulation 1)",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24% (Formulation 2)",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine hydrochloride 0.2%/Tears Naturale II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2011-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495338"
    },
    {
      "nct_id": "NCT05265910",
      "title": "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        },
        {
          "name": "loratadine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Tears Naturale",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andover Research Eye Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-12-14",
      "completion_date": "2022-04-23",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05265910"
    },
    {
      "nct_id": "NCT01470118",
      "title": "A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Conjunctivitis, Allergic"
      ],
      "interventions": [
        {
          "name": "alcaftadine 0.25% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "olopatadine 0.2% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-21",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01470118"
    },
    {
      "nct_id": "NCT00979615",
      "title": "Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vasomotor Rhinitis"
      ],
      "interventions": [
        {
          "name": "Olopatadine HCL (Patanase) Nasal Spray, 0.6%",
          "type": "DRUG"
        },
        {
          "name": "Azelastine HCl (Astelin) Nasal Spray, 137 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2009-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-05-10",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979615"
    },
    {
      "nct_id": "NCT01697969",
      "title": "Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Olopatadine hydrochloride ophthalmic solution, 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2012-09",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697969"
    },
    {
      "nct_id": "NCT00578331",
      "title": "Safety Study of Olopatadine Nasal Spray",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Perennial Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Olopatadine 0.6% nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 890,
      "start_date": "2006-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-31",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Waco, Texas",
      "locations": [
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00578331"
    },
    {
      "nct_id": "NCT02631551",
      "title": "Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "GSP 301 NS",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine HCl NS",
          "type": "DRUG"
        },
        {
          "name": "Mometasone furoate NS",
          "type": "DRUG"
        },
        {
          "name": "GSP 301 Placebo NS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glenmark Specialty S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1180,
      "start_date": "2016-03",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-09-25",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 37,
      "location_summary": "Mission Viejo, California • San Diego, California • San Jose, California + 28 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02631551"
    },
    {
      "nct_id": "NCT03320434",
      "title": "Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "PRT-2761 0.5%",
          "type": "DRUG"
        },
        {
          "name": "PRT-2761 1%",
          "type": "DRUG"
        },
        {
          "name": "Patanol",
          "type": "DRUG"
        },
        {
          "name": "Pred-forte",
          "type": "DRUG"
        },
        {
          "name": "PRT-2761 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2017-10-13",
      "completion_date": "2018-02-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-17",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03320434"
    },
    {
      "nct_id": "NCT04708821",
      "title": "DEXTENZA Therapy for Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bilateral Conjunctivitis (Disorder)"
      ],
      "interventions": [
        {
          "name": "Dexamethasone ophthalmic insert 0.4Mg",
          "type": "DRUG"
        },
        {
          "name": "0.2% loteprednol etabonate ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinical Research Center of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-04-30",
      "completion_date": "2021-09-02",
      "has_results": false,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Pompano Beach, Florida",
      "locations": [
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708821"
    },
    {
      "nct_id": "NCT01007253",
      "title": "Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "PL nasal spray",
          "type": "DRUG"
        },
        {
          "name": "fluticasone furoate (FF)",
          "type": "DRUG"
        },
        {
          "name": "PL eye drops",
          "type": "DRUG"
        },
        {
          "name": "olopatadine (OLO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2009-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2013-07-17",
      "last_synced_at": "2026-09-12T09:07:39.781Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01007253"
    }
  ]
}